Moderate to Severe Acne Pipeline Landscape Analysis, 2024, Featuring Emerging Therapies ASC40 (Ascletis Pharma), BTX 1503 (Botanix Pharmaceuticals), and More [Yahoo! Finance]
Dermata Therapeutics, Inc. (DRMA)
Company Research
Source: Yahoo! Finance
The global therapeutic market is on the cusp of transformation as novel insights emerge in the pipeline landscape for Moderate to Severe Acne treatment. This is highlighted in a current comprehensive report, focusing on the trajectory of research and development efforts in this domain. Disclosed within this report are the ambitious endeavors of 10+ pharmaceutical companies, each pushing the envelope with 10+ pipeline drugs devised to innovate acne treatments. Emerging Therapies on the Horizon As the Moderate to Severe Acne treatment segment undergoes rapid progression, emerging therapies display potential for a momentous impact. Notable among them is ASC40 by Ascletis Pharma Inc., a unique fatty acid synthase inhibitor with a penchant for curtailing lipogenesis, a vital aspect of sebum production linked to acne. Concurrently, Botanix Pharmaceuticals' BTX 1503, leveraging the novel Permetrex™ drug delivery technology, presents itself as a multifaceted opponent to acne's various ca
Show less
Read more
Impact Snapshot
Event Time:
DRMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRMA alerts
High impacting Dermata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DRMA
News
- Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation [Yahoo! Finance]Yahoo! Finance
- Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesAccesswire
- Dermata to Present at the Emerging Growth Conference on April 3, 2024 [Yahoo! Finance]Yahoo! Finance
- Dermata to Present at the Emerging Growth Conference on April 3, 2024Accesswire
DRMA
Sec Filings
- 6/7/24 - Form 8-K
- 6/7/24 - Form 424B5
- 6/5/24 - Form 8-K
- DRMA's page on the SEC website